Navigation Links
Regulus Provides Update on 'Road to the Clinic' Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
Date:5/14/2013

ing statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' financial position and programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 Regulus Therapeutics Inc.Selected Financial InformationCondensed Statement of Operations(In thousands, except share and per share data)Three months endedMarch 31,20132012(Unaudited)Revenues:Revenues under strategic alliances and collaborations$ 3,238$ 3,344Operating expenses:Research and development6,8834,603General and administrative1,905921Total operating expenses8,7885,524Loss from operations(5,550)(2,180)Other income (expense), net(1,689)(66)Loss before income taxes(7,239)(2,246)Income tax (benefit) expense(10)1Net loss$

(7,229)$

(2,247)Basic and diluted net loss per share$

(0.20)$

(13.06)Shares used to compute basic and diluted net loss per share35,872,606171,998 

 Regulus Therapeutics Inc.Condensed Balance Sheets(In thousands)March 31,2013December 31,2012(Unaudited)AssetsCash, cash equivalents and short-term investments$

90,715$

98,100Other current assets1,054829Noncurrent assets5,2584,589Total assets$

97,027$<
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
2. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
3. Regulus to Present at Future Leaders in the Biotech Industry Conference
4. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
5. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
6. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
7. Regulus to Present at Two Upcoming Investor Conferences
8. Regulus Appoints Mark G. Foletta to its Board of Directors
9. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
10. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
11. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... REDWOOD CITY, Calif., July 14, 2011 Codexis, Inc. (Nasdaq: ... in the 13th Annual Pacific Crest Global Technology Leadership Forum, ... Robert Lawson, Senior Vice President and Chief Financial Officer, will ... Biofuels and Renewable Chemicals," scheduled for August 8 at 12:30 ...
... ACCESS PHARMACEUTICALS, INC. (OTCBB: ... to develop treatments in areas of oncology, cancer supportive ... oral mucositis, MuGard , has been added to ... is now available with standard pharmacy benefit copayment.  Placement ...
Cached Medicine Technology:Access Pharmaceuticals MuGard Added to CVS Caremark's Pharmacy Benefit Network 2Access Pharmaceuticals MuGard Added to CVS Caremark's Pharmacy Benefit Network 3
(Date:7/9/2014)... of flatulence and have a reputation for being highly toxic, ... is now being being found to offer potential health benefits ... attacks and dementia. A new compound (AP39), designed and made ... future therapies, by targeting delivery of very small amounts of ... , Scientists in Exeter have already found that the ...
(Date:7/9/2014)... the most important organs in the human body. Its ... properly this is its synthesis function and ... this is its detoxification function. Lack of exercise and ... the liver. The resulting diseased cells can lead to ... failure. According to the German Liver Foundation, over five ...
(Date:7/9/2014)... prescription labels handed out by pharmacists may be ... medication, according to new research by the University ... the Blind)., The study, published recently in the ... on prescription medications dispensed by pharmacies do not ... By simply following recommended guidelines for font size, ...
(Date:7/9/2014)... , , , ... , , , , ... downrange from the firer and approximately 30cm from the bullet... , , ... , , , , ... , , , , , , University of Southampton researchers, with ...
(Date:7/9/2014)... The occurrence of allergic diseases has risen dramatically in ... are less exposed to microorganisms and have fewer infections ... system. , A study by researchers at Sahlgrenska Academy, ... three to examine maturation of the immune system in ... in rural areas of the Vstra Gtaland Region, half ...
Breaking Medicine News(10 mins):Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... March 17 JumpStart Inc. , ... progress of high growth early-stage businesses, and Case ... and technology validation fund at Case Western Reserve ... in Neuros Medical, Inc. , a Cleveland, OH ...
... Research Group, Inc. has been covering the biologics market ... series which are syndicated primary research reports ... and Rheumatologists. The company is now expanding these ... reports which aim to compare self-reported treatment patterns ...
... in Mexico for Minimally Invasive Treatment for Prostate ... elite urologistsCHARLOTTE, N.C., March 16 Mexico HIFU ... international entities of USHIFU, a global leader in ... focused ultrasound (HIFU) technologies, will host the very ...
... 16 Star Scientific, Inc. (Nasdaq: STSI ... with the Securities and Exchange Commission. The company reported ... unchanged from net sales for 2007. However, volume sales ... and Stonewall(R), increased 7.8% in 2008 compared to 2007. ...
... March 16 /PRNewswire-Asia-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: ... that the Company is calling its $12.4 million of ... Notes"). In addition, the,Company announced the completion of ... Exchanged $1.0 million in principal amount 10.0% senior secured, ...
... in St. Louis and Johns Hopkins University, in partnership with Experience Corps, has showed that people over 55 ... Click here for more information. , , ... , , , , ... , , , ...
Cached Medicine News:Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 2Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 3Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 4Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 5Health News:BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis 2Health News:High Intensity Focused Ultrasound Physician Training Seminar in Mexico City 2Health News:Star Scientific Files Annual Financial Report 2Health News:Star Scientific Files Annual Financial Report 3Health News:Star Scientific Files Annual Financial Report 4Health News:BMP Sunstone Exchanges and Calls Outstanding Notes Due May 2009 2Health News:Researchers find sustained improvement in health in Experience Corps tutors over 55 2Health News:Researchers find sustained improvement in health in Experience Corps tutors over 55 3Health News:Researchers find sustained improvement in health in Experience Corps tutors over 55 4
... PS+ lead series are endocardial ... the best characteristics of polyurethane ... polyurethane outer insulation provides a ... lubricity while the silicone inner ...
The Vitatron Slimtine S lead series are endocardial leads with an excellent history of reliability and optimal handling en pacing performance....
Unipolar Atrial "J" Lead...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: